title: [Treatment outcome of peptide vaccination for advanced colorectal cancer].
abstract: Complementary DNA( cDNA) microarray technology coupled with laser microdissection has been used to identify human leukocyte antigen (HLA)-A24-restricted epitope peptides as potential targets for cancer vaccination in colorectal cancer patients. These antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34). We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer. The vaccinations were well tolerated without any serious adverse events. There were long-term survivors in the group showing cytotoxic T lymphocyte (CTL) responses against both RNF43 and TOMM34, as well as in the group showing CTL responses against either RNF43 or TOMM34. A new study has been planned to obtain more immunological responses. We started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.
authors.affiliation: Dept. of Surgery, Kinki University Faculty of Medicine.
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Sugiura
authors.forename: Keisuke
authors.initials: K
authors.lastname: Inoue
authors.forename: Akihiro
authors.initials: A
authors.lastname: Kogita
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Jinichi
authors.initials: J
authors.lastname: Hida
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Okuno
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sukegawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin